dostarlimab,cobolimab,tsr 022
tesaro,gsk
['amber', 'dostarlimab', 'cobolimab']
anti tim-3 antibody cobolimab shows promising safety &amp; preliminary efficacy in combination w/ pd-1 inhibitor dostarlimab in the phase 1 amber trial. #asco22 #ascodailynews #immunotherapy
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.